{"name":"Minnesota Eye Consultants, P.A.","slug":"minnesota-eye-consultants-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bepreve 1.5% Ophthalmic Solution","genericName":"Bepreve 1.5% Ophthalmic Solution","slug":"bepreve-1-5-ophthalmic-solution","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Refresh Tears 0.5% Lubricant Eye Drops","genericName":"Refresh Tears 0.5% Lubricant Eye Drops","slug":"refresh-tears-0-5-lubricant-eye-drops","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"}]}],"pipeline":[{"name":"Bepreve 1.5% Ophthalmic Solution","genericName":"Bepreve 1.5% Ophthalmic Solution","slug":"bepreve-1-5-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Refresh Tears 0.5% Lubricant Eye Drops","genericName":"Refresh Tears 0.5% Lubricant Eye Drops","slug":"refresh-tears-0-5-lubricant-eye-drops","phase":"marketed","mechanism":"Refresh Tears provides ocular lubrication by supplementing natural tear film to relieve dry eye symptoms.","indications":["Dry eye disease / Keratoconjunctivitis sicca","Ocular irritation and discomfort"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxOSVRXMWpzcEJQdUI2V001dDk5V1NjTTY2blpMV2lZSjFHeFF2ZXEwWUVhZHZ1MHhCYi1SXzRoUlMzYjZvVDJIUGhhM0JHYXBkc3NsLVMxNlpYRXRHb2hkSFQtWkJMWWljWjM4MWlnLVRRWVZZa1IxN1lhX09FaExTbHpFZDZ3cEh3OGpvTUZ3WE5QVkpsYTA5SnpYODd2R2dLUm02dTViVnp0Qzg2clNqOGJzS1NQeU1MRnp0aUlua3lFVGRKY28wVzBQeC12MWdicDQ2SmxCSm81TmhDWm1VeEZ0alI3TnJDRGJfdUlSV2NHZjNpYnRCWnM0eDlOcHFyTGRsTGVoR0JNVVY2WERRTGEwdWlwenBwWXNBd3Z4UlY0Sy1EbGhiRkFsMFRQdzhiRWxqTlVkRHBmR19qZjVIMnRDWVZiaW0wWFRBendCQ0pBajd6UGM5dQ?oc=5","date":"2023-12-18","type":"pipeline","source":"businesswire.com","summary":"Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States - businesswire.com","headline":"Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPMDlHNWNtVFRIV09oaU5Kb3BtVHFoc1NRbWZ3THJqNW5iS0JpQWd6TnhCRU93ZEpkT0REMVRKeUMtN0FWejhrV1h3bmswZ2tCdkpWQmlIbnRIZERVNVk5OWN4OFJ1bkVWS0Z0NWNxZWpfbnNYdjNHZnFPQnFMby1VUW5vOHVfUWt4MkVQWWNPRUdDaENOcjhiWnh1ckRzSmt1WW1kZEFIRUtZeGZOUjNiX0dkdkVSQVJvaDdiUTNnQVptZw?oc=5","date":"2016-08-16","type":"pipeline","source":"Healio","summary":"Ophthalmologists who invest in physician assistants reap valuable rewards - Healio","headline":"Ophthalmologists who invest in physician assistants reap valuable rewards","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}